Stocks Aim To Attain Street Attentions: Mellanox Technologies (NASDAQ:MLNX), Palatin Technologies (NYSE:PTN)

Mellanox Technologies, Ltd. (NASDAQ:MLNX) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -0.35% to $49.33. Mellanox Technologies, Ltd. (MLNX) reported that its ConnectX-5 100Gb/s Ethernet Network Interface Card has achieved 126 million packets per second of record-setting forwarding capabilities running the open source Data Path Development Kit. The share price of MLNX attracts active investors, as stock price of week volatility recorded 2.79%. The stock is going forward to its 52-week low with 27.29% and lagging behind from its 52-week high price with -11.60%.

Palatin Technologies, Inc. (NYSE:PTN) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 1.95% to close at $0.38 with the total traded volume of 956472 shares. AMAG Pharmaceuticals, Inc. (AMAG) and Palatin Technologies, Inc. (PTN) said Monday that both Phase 3 RECONNECT studies (301, 302) of Rekynda, or bremelanotide, met co-primary end points and demonstrated important improvement in key symptoms of hypoactive sexual desire disorder.

Rekynda is an investigational product being developed as a potential on-demand treatment for pre-menopausal women diagnosed with hypoactive sexual desire disorder or HSDD.AMAG Pharma and Palatin Technologies said that additional results from the Phase 3 RECONNECT Studies of Rekynda were presented at the International Society for the Study of Women’s Sexual Health or ISSWSH Annual Meeting in Atlanta, Georgia.

Both Phase 3 studies met their co-primary endpoints of improvements in desire, as measured by the Female Sexual Function Index – Desire domain (FSFI-D), and decrease in associated distress, as measured by the Female Sexual Distress Scale – Desire/Arousal/Orgasm (FSDS-DAO).These results were previously declared in November 2016 by Palatin Technologies who sponsored the studies prior to entering into a licensing contract with AMAG for the North American rights to Rekynda. The firm has institutional ownership of 20.20%, while insider ownership included 2.90%. PTN attains analyst recommendation of 1.70 with week’s performance of -4.00%.

 

About Blake Escott

Blake Escott holds junior writer position in SWR. Before joining Streetwise Report, he was a freelance content Writer. He has high-level copywriting experience and particularly experienced in proofreading and editing. He covers news about different companies including all US market sectors. Interests: Commodities, Energy stocks, Sector-wise Stocks analysis, Utilities

Leave a Reply

Your email address will not be published. Required fields are marked *